β-Catenin Signaling in Hepatocellular Carcinoma: Mechanisms of Therapeutic Resistance and Emerging Therapeutic Strategies
Abstract
Simple Summary Hepatocellular carcinoma (HCC), the predominant type of liver cancer, is one of the leading causes of cancer-related deaths worldwide, and many patients are diagnosed only after the disease has reached an advanced stage. Although new treatments, including targeted therapies and immunotherapy, have improved patient care, many tumors eventually become resistant, limiting long-term treatment success. Increasing evidence has identified β-catenin, a protein involved in normal cell growth and tissue maintenance, as an important contributor to HCC development and resistance to multiple forms of therapy. This review summarizes current knowledge of how abnormal β-catenin signaling promotes tumor growth, supports cancer cell survival, and reduces treatment effectiveness. It also discusses emerging therapeutic strategies designed to inhibit β-catenin signaling or counteract its downstream effects. A better understanding of these mechanisms may guide the development of more effective treatment combinations, improve patient selection for existing therapies, and support future research aimed at overcoming therapeutic resistance in liver cancer.